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Abstract
Ovarian carcinoma reflects the biggest challenge among the field of gynecologic oncol-
ogy. It represents the most common death cause of genital carcinomas throughout years. 
The major classification consists of epithelial and non-epithelial types. Due to the histo-
logic origin, epithelial types of ovarian carcinoma are endometrioid, serous-mucinous, 
and clear cell types. Due to intense metastatic infiltration and rapid tumor spread, clear 
cell ovarian carcinoma constitutes type of lesion with the most poor prognosis, decreased 
overall survival, decreased free survival, and poor quality of life of the patient. The 
metastatic infiltration is strongly accompanied with all significant prognostic factors. 
All biochemical pathways at the time of the infiltration are correlated with tumor size, 
lymphatic spread, staging of the lesion, histologic type, and grade of differentiation of 
the lesion.
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1. Introduction
According to current literature, ovarian cancer represents a high mortality neoplasm in gyne-
cologic malignancy. The 2017 incidence estimates 22,400 new cases in the United States [1]. 
The increased mortality rate is strongly accompanied with staging of the lesion at the time 
of the diagnosis. Many predisposition factors influence the therapeutic mapping. Age of the 
patient, parity, staging, cluster of differentiation, surgical margins, and lymphatic infiltration 
consist the gold standard of therapeutic strategy (Figure 1).
The frequency of the lesion increases in ages between 55 and 65 years old. There are also 
studies implicating younger or older patients. The lesion is more frequent in developed 
countries of the Western World and less in Asian countries [2]. Ovarian neoplasms express 
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a wide variety. The most practical and useful classification depends on the histogenetic ori-
gin. Histological classification represents an autonomic entity with independent subtypes, 
disease-free survival, and quality of life of the patient (Figure 2).
On the other hand, depiction of histopathology, immunohistochemistry, and molecular 
genetic analysis reveal five basic types of ovarian carcinoma: high-grade serous carcinoma 
(HGSC 70%), endometrioid carcinoma (EC 10%), clear cell carcinoma (CCC 10%), mucinous 
carcinoma (MC 3%), and low-grade serous carcinoma (LGSC <5%) [3] (Table 1).
All recent conducted studies with classification parameter of the histogenetic origin express 
in 90% of cases the epithelial type as the most common type of ovarian carcinoma. Many use-
ful tools, such as physical examination, transvaginal ultrasonography, Ca-125 levels, abdomi-
nal CT, or MRI, are mandatory in order to establish a more accurate clinical diagnosis [4]. 
Depending on clinical diagnosis, proper therapeutic mapping can be performed.
Among histologic subtypes of epithelial ovarian carcinoma, the most significant type with 
chemoresistance and poor prognosis consists clear cell ovarian carcinoma (CCC).
Clear cell carcinoma represents a distinct entity of epithelial ovarian carcinoma with an inci-
dence less than 5% of all ovarian lesions [5]. Gold standard concerning therapeutic strategy 
of epithelial ovarian cancer and, respectively, of clear cell carcinoma is based on abdominal 
total hysterectomy, bilateral salpingo-oophorectomy, partial omentectomy with peritoneal 
sampling, and lymphadenectomy, adding cytoreductive surgery in advanced cases.
In many cases, surgical mapping for clear cell carcinoma remains a controversial issue. Many 
studies underline the decreased impact of adjuvant chemotherapy in patients with stage I 
clear cell carcinoma and the relation of the lesion with overall survival [6]. The ultimate scope 
of cytoreductive surgery in patients with clear cell carcinoma reflects the acknowledgment of 
high-risk patients correlated with recurrence of the lesion.
Figure 1. Prognostic factors in ovarian cancer. Ozols RF et al. Cancer Principles and Practice of Oncology. 5th ed. 
1997;1510.
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The significant role to metastatic pathways of clear cell carcinoma and the therapeutic map-
ping reflects the histologic configuration of the lesion. Histologic figures of clear cell carcino-
mas express clear cytoplasm with large nuclei and prominent nucleoli and a partial hobnail 
appearance (Figure 3).
Figure 2. (A) Histological subtypes of ovarian cancer and (B) widely accepted epithelial ovarian cancer classification 
paradigm based on clinic, pathologic, and molecular evidence that type I and type II tumors develop through different 
pathways. *Indicates rare tumor. †Mucinous and malignant Brenner tumors are considered to be possible exceptions that 
may arise from transitional cells at or close to the junction of the fallopian tube and the peritoneum. Kurman RJ, Shih Ie 
M. The dualistic model of ovarian carcinogenesis: Revisited, revised, and expanded. Am. J. Pathol. 2016, 186, 733–747.
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2. Discussion
Despite poor prognosis, overall survival, and quality of life of the patient, all conducted stud-
ies are focusing on the pathologic and metastatic pathways of the lesion. This issue remains 
controversial.
Figure 3. Histology of the original tumor. The left ovarian tumor is a clear cell carcinoma, with cells harboring clear 
cytoplasm and a partial hobnail appearance, as shown by hematoxylin and eosin (HE) staining ((a) bar = 200 μm; (b) 
bar = 50 μm). Yamada T et al. Characterization of a Novel Cell Line (HCH-3) Derived from a Human Ovarian Clear Cell 
Carcinoma. Yamada et al., J Carcinogene Mutagene 2017.
HGSC LGSC MC EC CCC
Risk factors BRCA1/BRCA2 ? ? HNPCC2 ?
Precursor lesions Tubal intraepithelial 
carcinoma
Serous borderline 
tumor
Cystadenoma/
borderline tumor?
Atypical 
endometriosis
Atypical 
endometriosis
Pattern of spread Very early 
transcoelomic spread
Transcoelomic 
spread
Usually confined 
to the ovary
Usually 
confined to the 
pelvis
Usually confined 
to the pelvis
Molecular 
abnormalities
BRCA, p53 BRAF, KRAS KRAS, HER2 PTEN, ARIDIA HNF1, ARIDIA
Chemosensitivity High Intermediate Low High Low
Prognosis Poor Intermediate Favorable Favorable Intermediate
Rat J. New insights into ovarian cancer pathology. Annals of Oncology 23 (Supplement 10): x111-x117, 2012.
HGSC, high-grade serous carcinoma; LGSC, low-grade serous carcinoma; MC, mucinous carcinoma; EC, endometrioid 
carcinoma; CCC, clear cell carcinoma. aHereditary nonpolyposis colorectal carcinoma.
Table 1. Ovarian carcinoma: clinical and molecular features of the five most common types.
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Szubert et al. described the correlation of endometriosis and clear cell ovarian carcinoma [7]. 
All the efforts lead to correlate the risk factors of endometriosis and clear cell carcinoma. 
We must never forget the role of endometriosis as trigger point and prominent risk factor of 
ovarian cancer. On the other point, many conducted studies depict the opposite statistic con-
clusion, gaining the impression of controversial issue. Zafrakas et al. correlated all the current 
data without an informative meta-analysis [8]. More conducted studies were mandatory in 
order to establish such a hypothesis.
Critical points of clear cell ovarian carcinoma remain the understanding of carcinogenesis, the 
genetic changes of the lesion, and most of all the mechanisms of target therapy.
Mabuchi et al. described and correlated all the critical genetic changes in clear cell carcinoma 
[9] (Table 2). Focusing on gene mutation, pathway bridge, and following tumor implications, 
we can explain the carcinogenesis of clear cell carcinoma.
Focusing on tumor angiogenesis, many conducted studies described targeted antibodies as 
therapeutic shield toward the production of tumor vessels [10]. Classical examples of target 
therapy consist monoclonal antibodies against vascular endothelial growth factor (VEGF), 
platelet-derived growth factor (PDGF), fibroblast growth factor (PDGF), and angiopoietin/
Tie2 receptor complex [11]. Therapeutic philosophy depends on adjunction of monoclonal 
antibodies with growth factors, in order to prohibit tumor angiogenesis and infiltration. The 
emphasis in this procedure reflects the significant chemoresistance and poor prognosis of the 
lesion. The results of this target therapy remain controversial, justifying the significance of 
therapeutic strategy (Figure 4).
All therapeutic strategies consisted of overall survival, patient’s quality of life and, in young 
ages with early stage lesion, the fertility-sparing surgery [12]. There are extreme selected indi-
cations, performing this surgical dissection.
Nasioudis et al. using the National Cancer Institute’s Surveillance Epidemiology and End 
Results (SEER) database managed to perform the safety of fertility-sparing surgery in stages 
IA and IC of ovarian clear cell carcinoma [13]. The comparison, in patients with stage I ovar-
ian clear cell carcinoma with preservation of the uterus and ovaries with general survival 
outcome, did not lead to statistical conclusion. However, further conducted studies are man-
datory, in order to establish this type of surgical strategy in young female patients with stage 
IA or IC ovarian clear cell carcinoma.
Besides understanding the carcinogenesis of the lesion, the biochemical pathways, and the 
effort of fertility-sparing surgery in young female patients, we must mention the advanced 
metastatic opportunity of the lesion.
Lymphatic, hematogenic, and endoperitoneal infiltration of the lesion can lead to advanced 
metastatic possibilities. First of all, the lesion can penetrate the local anatomic organs: the 
salpinx, round ligament, uterus, peritoneal wall, colon, or even the omentum [14].
The most common, premature, and characteristic route of infiltration consists of the endoperi-
toneal [15]. All neoplasmatic cells are deafened, entering the peritoneal cavity. Through respi-
ratory movements, endoperitoneal fluid with neoplasmatic cells finally reaches all epithelial 
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areas and especially the hemidiaphragms. Final result, building of metastatic lesions as 
metastatic plaque or in advanced lesion as neoplasmatic “cake” (Figure 5). Through the right 
hemidiaphragm, the lesion can be spread in the pleura area, provoking hydrothorax or reach-
ing the subclavian lymph nodes.
Usual distant organs with signs of infiltration are liver, lungs, and lymph nodes beyond the 
pelvic and para-aortic chains. Lymphatic spread of this lesion is common. The spread route 
follows the lymphatic vessels of ligamentum teres uteri or the lymphatic vessels of the right 
hemidiaphragm. The most common areas are pelvic lymph nodes with less frequent inguinal, 
axillary, or subclavian lymph nodes.
Hematogenic infiltration is strongly connected with advanced stages of the lesion. In these 
cases, the most common is liver and lung infiltration. In extreme advanced stages of the 
lesion, there are cases of skin or brain infiltration.
Nam et al. reported skin metastases in ovarian clear cell carcinoma as severe advanced meta-
static area of the lesion [16]. Infiltration of these organs reflects severe decrease of disease-free 
survival, overall survival, and quality of life of the patient.
Gene Gene type Change Pathways affected Roles in tumor development
ARID1A Tumor 
suppressor
Mutation in 
−50%
SWI/SNF chromatin 
complex
Modulate accessibility of 
transcription factors to 
promoters
PIKECA Oncogenic Mutation in 
−40%
PI3K/AKT/mTOR Proliferation/survival
PPP2R1A Oncogenic Mutation in 7% AKT/MAPK Proliferation/survival
KRAS Oncogenic Mutation in 5% AKT/MAPK Proliferation/survival
BRCA1/BRCA2 Tumor 
suppressor
Mutation in 6% DNA repair Genomic instability
PTEN Tumor 
suppressor
Mutation in 5% PI3K/AKT/mTOR Proliferation/survival
CDKN2A/CDKN2B Tumor 
suppressor
Deletion in 9% CDK inhibitors (p15/
p16)
Cell cycle progression
ZNF217 Oncogenic Amplification 
in 36%
ZNF217 Antiapoptosis
PPM1D Oncogenic Amplification 
in 10%
P53-mediated apoptosis Antiapoptosis
AKT2 Oncogenic Amplification 
in 14%
AKT/mTOR Proliferation/survival
MET Oncogenic Amplification 
in 37%
AKT/MARK Proliferation/survival
ARID1A, AT-rich interactive domain 1A; BRCA, breast cancer; CDK, cyclin-dependent kinase; CDKN, cyclin-dependent 
kinase inhibitor; MAPK, mitogen-activated protein kinases; mTOR, mammalian target of rapamycin; PIK3CA, 
phosphatidylinositol-45-bisphosphate 3-kinase catalytic subunit alpha; PI3K, phosphatidylinositol 3-kinase; PPM1D, 
protein phosphatase 1D; PPP2R1A, protein phosphatase 2 regulatory subunits 1A; PTEN, phosphatase and tensin 
homolog; SWI/SNF, SWItch/sucrose non-fermentable; ZNF217, zinc finger protein 217.
Table 2. Mabuchi S, Sugiyama T, Kimura T. Clear cell carcinoma of the ovary: molecular insights and future therapeutic 
perspectives. J Gynecol Oncol. 2016May; 27(3); e31.
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Postoperative treatment of clear cell ovarian carcinoma deviates, representing a distinct entity 
from other epithelial ovarian carcinomas. Reflecting a chemoresistant phenotype, the final 
prognosis of the lesion is poor, decreasing the quality of life of the patient. In cases of clear cell 
Figure 4. Weiner Building better monoclonal antibody-based therapeutics. Nature Reviews Cancer 15,361–370 (2015).
Figure 5. Omental cake (arrows) and ascites in a patient with peritoneal metastases derived from ovarian cancer. Levy 
Angela. Chief Gastrointestinal Radiology, Department of Radiologic Pathology, Armed Forces Institute of Pathology, 
Washington DC, Associate Professor of Radiology, Uniformed Services University of the Health Sciences, Bethesda, MD.
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carcinoma, gold standard combination with paclitaxel and carboplatin consists a not promis-
ing therapeutic strategy. Irinotecan hydrochloride, a topoisomerase I inhibitor, reflects an 
alternative solution regarding the postoperative treatment of clear cell carcinoma [17] (first-
line chemotherapy for clear cell carcinoma) (Table 3).
Many conducted studies managed to express the synergic effects of the combined therapeutic 
strategy of irinotecan and cisplatin (Table 4).
In cases of recurrent clear cell carcinoma, therapeutic mapping is very disappointed. Even in 
cases of sensitive platinum disease, the use of antineoplasmatic agents offers a response rate 
not up to 10% [18] (second-line chemotherapy for clear cell carcinoma).
Regimen Author Year Response/number of patient, response rate
Conventional platinum based Goff (28) 1996 1/6, 17%
Sugiyama (29) 2000 3/27, 11%
Ho (30) 2004 4/15, 27%
Takano (9) 2006 5/30, 17%
Taxane-platinum Ecomoto (31) 2003 2/9, 22%
Ho (30) 2004 9/16, 56%
Utsunomiya (32) 2006 8/15, 53%
Takano (9) 2006 9/28, 32%
Irinotecan-cisplatin Takano (9) 2006 3/10, 30%
Takano et al. Clear cell carcinoma of the ovary: Is there a role of histology-specific treatment? Journal of Experimental & 
Clinical Cancer Research 2012, 31:53
Table 3. Response rates of primary chemotherapy for clear cell carcinoma.
Regimen Author Year Response/number of patient, response rate
Megestrol acetate Malailak (45) 2001 2/10, 20%
Cyclophosphamide + cisplatin Takano (46) 2008 1/9, 11%
Irinotecan + platinum Sugiyama (29) 1998 1/3, 33%
Takano (46) 2008 2/15, 13%
Etoposide + platinum Takano (46) 2008 2/13, 15%
Paclitaxel + carboplatin Utsunomiya (32) 2006 3/13, 23%
Crotzer (43) 2007 2/7, 29%
Gemcitabine Crotzer (43) 2007 1/9, 11%
Yoshino (47) 2012 1/5, 20%
Docetaxel + irinotecan Yoshino (47) 2012 1/11, 9%
Temsirolimus Takano (46) 2011 1/5, 20%
Takano et al. Clear cell carcinoma of the ovary: Is there a role of histology-specific treatment? Journal of Experimental & 
Clinical Cancer Research 2012, 31:53.
Table 4. Response rates of salvage chemotherapy for recurrent or refractory clear cell carcinoma.
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The main objective of the previous study was the presentation and implementation of an 
epithelial-type ovarian carcinoma with specific metastatic pathways, prohibiting especially 
episodes of target therapy. New scientific keys, in the near future, will unlock unknown bio-
chemical mechanisms and give answers to many questions, concerning the understanding of 
carcinogenesis of this lesion.
3. Conclusion
Ovarian clear cell carcinoma represents a rare histological entity with extreme chemoresis-
tance and poor prognosis in correlation with overall survival and quality of life of the patient. 
Better understanding of metastatic and biochemical pathways of the lesion could schedule 
a proper therapeutic mapping. Further conducted studies are needed, in order to establish 
such strategy.
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